Nirmatrelvir + ritonavir (Paxlovid)
- Status:
- Red
- Decision Date:
- April 2023
Comments
RED: NICE TA787 -
oral preparation for non-hospitalised patients. To be prescribed by clinicians working in the Covid Medicines Delivery Unit onlyRed Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again